Health Care

Alterity Therapeutics: Explore its volatile stock, negative P/E and the battle to deliver Alzheimer’s therapies amid financial challenges.

Viromed Medical AG’s manager‑sale spurs a 4.9 % share rally, showcasing executive transparency and hinting at future upside.

iSpecimen’s new direct‑shipment model cuts biospecimen transit times by up to 85% and drove a 91% surge in its share price.

CorMedix, a Nasdaq‑listed biopharma, showcases its cutting‑edge anti‑infective pipeline—DefenCath®, REZZAYO®—and strategic Melinta acquisition at the 2026 Needham Virtual Healthcare Conference, spotlighting growth in infectious & inflammatory therap…

Explore KALA BIO’s dramatic stock plunge, negative P/E and the hurdles facing its mucosal drug‑delivery tech—what it means for investors and the future of biotech.

Virax Biolabs, a Nasdaq‑listed biotech, focuses on viral diagnostics, PPE and immunology‑based products, navigating tough markets while driving innovation in disease prevention and detection.

Bluejay Diagnostics enrolls 624 of 750 SYMON‑II trial patients, advancing the Symphony IL‑6 sepsis test toward regulatory approval and improved critical‑care outcomes.

Creative Medical Technology Holdings: regenerative medicine promise meets steep financial hurdles. 2026 stock slump, negative P/E, and investor caution reveal the risks and potential of a biotech innovator.

Vanda Pharmaceuticals launches Thetis trial for tradipitant, a small‑molecule anti‑emetic, and challenges FDA’s proposed review‑time extension, aiming to speed GLP‑1 therapy access.

Merck KGaA’s resilient healthcare pipeline, expanding lipid‑nanoparticle platform and dividend‑friendly policy drive medium‑term value amid market volatility.